Skip to main content
. 2015 Nov 23;10(11):e0143441. doi: 10.1371/journal.pone.0143441

Fig 1. Expression and prognosis of miR-203 for bladder cancer patients treated with cisplatin-based chemotherapy.

Fig 1

(A) miR-203 levels were detected by RT-qPCR method and normalized against U6 RNA in 108 cases of bladder cancer tissues. Levels of miR-203 in progression group were significantly lower than those in non-progression group (P<0.001, Mann-Whitney U test). (B) ROC curve distinguished patients with progression from those without progression using miR-203, with an area under the ROC curve value of 0.839 (95% CI, 0.756–0.903). (C, D) Kaplan-Meier PFS and OS curves based on miR-203 expression of bladder cancer patients. The optimal cut off value (0.345) calculated by ROC analysis was used to classify the patients as high and low miR-203 expression groups. Low expression of miR-203 was significantly correlated with shortened PFS or OS (Both P<0.001, log-rank test).